ArticleACS omega2025
Antidiabetic Activity and Inhibitory Effects of Derivatives of Advanced Aminoguanidine Glycation.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mung Bean Seed Coat Extract Promotes Diabetic Wound Healing in High-Glucose-Exposed HaCaT Keratinocytes.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aminoguanidine is a drug that prevents the formation of AGEs by reacting with initial glycation products and is effective in improving proteinuria and vessel elasticity, preventing diabetic retinopathy, and treating patients with diabetic nephropathy. Structural modifications of this molecule were carried out, and 19 derivatives were studied to present a potential hypoglycemic and antiglicante effect, preventing such complications for diabetics. For this purpose, an in vitro cytotoxicity test was initially carried out by colorimetric assay with MTT [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium], in macrophages of the J774 lineage. The AGEs were produced in vitro from the junction of glucose with bovine serum albumin and tested for evaluation of the antiglicante activity with reading in a fluorescence spectrophotometer. Derivatives with the best in vitro response were submitted to in vivo acute toxicity tests with Wistar rats and later evaluation of their antidiabetic and antiglycant potential in rats with streptozotocin-induced diabetes. After euthanasia, the heart, kidney, liver, and pancreas were removed for histopathological examination, and the blood for blood count and glycated hemoglobin, glucose, insulin, triglycerides, total cholesterol, HDL cholesterol, serum albumin, fructosamine, TGO, TGP, and GGT were collected. It is possible to conclude that the studied derivatives have the potential for the production of a drug that can be produced with them or associated with them and that is capable of reducing the glycemic indices and, at the same time, having an antiglicant action protecting individuals from macro- and microvascular complications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.